Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 286 participants.

Also called NCT03070782

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 286 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03070782
  • EudraCT 2016-003373-18
Other papers using this trial's data
  • Lipoprotein(a) Reduction in Persons with Cardiovascular Disease The New England journal of medicine, 2020-01-16 DOI, PubMed 31893580

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Denmark, Germany, Netherlands (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03070782. Randomized; triple masking; primary purpose treatment. Start 2017-03-07 (actual); primary completion 2018-07-26 (actual). Results posted on 2020-10-30.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease
Condition
Elevated Lipoprotein(a)
Condition
Cardiovascular Disease
Intervention (Drug)
ISIS 681257
Intervention (Drug)
Placebo
Lead sponsor
Akcea Therapeutics (class: industry)
Collaborator
Ionis Pharmaceuticals, Inc. (class: industry)

Record details

Record id
cardio:ct-nct03070782
Content hash
d69fdc4d938e81068c1ea20c7ae06838b2413bce3c0551c34c50ec0d45a0682c